Pharvaris has raised about $201.2 million through an upsized public offering of its shares, including the sale of over 9.5 million ordinary shares and pre-funded warrants for half a million shares. The process will help Pharvaris continue developing its oral treatments for diseases caused by bradykinin, such as hereditary angioedema (HAE)..

Pharvaris通过扩大规模的股票公开发行筹集了约2.012亿美元，其中包括出售超过950万股普通股和50万股预融资权证。这一过程将帮助Pharvaris继续开发针对缓激肽引起的疾病（如遗传性血管性水肿（HAE））的口服治疗药物。

Pharvaris

法瓦里斯

is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

是一家处于后期阶段的生物制药公司，正在开发新型的口服缓激肽B2受体拮抗剂，以满足那些患有缓激肽介导疾病（如遗传性血管性水肿（HAE）和因C1抑制剂缺乏导致的获得性血管性水肿（AAE-C1INH））的患者未被满足的需求。

The company intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3)..

该公司旨在提供类似注射剂的疗效™ 和类似安慰剂的耐受性，并结合口服疗法的便利性，以预防和治疗缓激肽介导的血管性水肿发作。凭借在HAE的II期预防和按需治疗研究中的积极数据，Pharvaris目前正在关键的III期研究中评估deucrictibant用于预防HAE发作（CHAPTER-3）以及在关键III期研究中评估其按需治疗HAE发作（RAPIDe-3）的疗效和安全性。

The company has closed its previously announced

公司已经关闭了之前宣布的

upsized underwritten public

增额包销公开发行

offering of 9,562,500 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,312,500 ordinary shares) and pre-funded warrants to purchase 500,000 ordinary shares. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $201.2 million.

发行9,562,500股普通股（其中包括承销商全额行使购买额外1,312,500股普通股的选择权）以及可购买500,000股普通股的预资助认股权证。在扣除承销折扣、佣金和其他发行费用之前，Pharvaris从此次发行中获得的总收益约为2.012亿美元。

All securities in the offering were sold by Pharvaris..

此次发行中的所有证券均由 Pharvaris 出售。

As initially indicates, the company intends to use the net proceeds of this offering primarily to fund research and development expenses for its late-stage clinical programs, the hiring of a sales and marketing team in the U.S. and related commercialization expenses and for working capital and general corporate purposes..

如最初所示，公司打算将此次发行的净收益主要用于资助其后期临床项目的研究和开发费用、在美国组建销售和营销团队及相关商业化支出，以及用于营运资金和一般公司用途。

(Press release)

（新闻稿）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送